Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1575468 | 0.90 | ALDH1A1 (0.72) | ALDH1A1RAB9AFAAHTP53POLB | |
| SCHEMBL1575269 | 0.89 | RAB9A (0.73) | ALDH1A1RAB9AFAAHTP53POLB | |
| SCHEMBL1575305 | 0.89 | RAB9A (0.73) | ALDH1A1RAB9AFAAHTP53POLB | |
| SCHEMBL1575230 | 0.87 | RAB9A (0.50) | ALDH1A1RAB9AKDM4EMAPTTP53 | |
| SCHEMBL1576088 | 0.86 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTTP53POLB | |
| SCHEMBL1575467 | 0.86 | KMT2A (0.60) | ALDH1A1RAB9AKDM4EL3MBTL1MAPT | |
| SCHEMBL1575015 | 0.86 | ALDH1A1 (0.60) | ALDH1A1RAB9AKDM4EL3MBTL1MAPT | |
| SCHEMBL1575814 | 0.86 | MEN1 (0.62) | ALDH1A1RAB9AMAPTFAAHPOLB | |
| SCHEMBL1575186 | 0.85 | KDM4E (0.67) | ALDH1A1RAB9AKDM4EMAPTFAAH | |
| SCHEMBL4307000 | 0.85 | ALDH1A1 (0.78) | ALDH1A1RAB9AKDM4EL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | ALDH1A1 1445/4885RAB9A 898/4885KDM4E 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.